

Sven Becker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7727405/publications.pdf>

Version: 2024-02-01

28
papers

678
citations

567281

15
h-index

580821

25
g-index

28
all docs

28
docs citations

28
times ranked

1198
citing authors

#	ARTICLE	IF	CITATIONS
1	Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 1707.	7.1	129
2	Targeting CDK9 for Anti-Cancer Therapeutics. <i>Cancers</i> , 2021, 13, 2181.	3.7	56
3	Mitotic arrest and slippage induced by pharmacological inhibition of Polo-like kinase 1. <i>Molecular Oncology</i> , 2015, 9, 140-154.	4.6	47
4	PLK1 has tumor-suppressive potential in APC-truncated colon cancer cells. <i>Nature Communications</i> , 2018, 9, 1106.	12.8	47
5	Non-mitotic functions of polo-like kinases in cancer cells. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188467.	7.4	45
6	Ligand stimulation of CD95 induces activation of Plk3 followed by phosphorylation of caspase-8. <i>Cell Research</i> , 2016, 26, 914-934.	12.0	35
7	The lipid-transfer protein Nir2 enhances epithelial-mesenchymal transition and facilitates breast cancer metastasis. <i>Journal of Cell Science</i> , 2014, 127, 4740-9.	2.0	32
8	Boosting the apoptotic response of high-grade serous ovarian cancers with <i>CCNE1</i> amplification to paclitaxel <i>in vitro</i> by targeting APC/C and the pro-survival protein MCL1. <i>International Journal of Cancer</i> , 2020, 146, 1086-1098.	5.1	29
9	Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability. <i>Neoplasia</i> , 2019, 21, 363-375.	5.3	27
10	The role of caspase-8 in the tumor microenvironment of ovarian cancer. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 303-318.	5.9	25
11	Synthetic lethality in <i>CCNE1</i> -amplified high grade serous ovarian cancer through combined inhibition of Polo-like kinase 1 and microtubule dynamics. <i>Oncotarget</i> , 2018, 9, 25842-25859.	1.8	24
12	Modern Myoma Treatment in the Last 20 Years: A Review of the Literature. <i>BioMed Research International</i> , 2018, 2018, 1-6.	1.9	22
13	From Clinical Symptoms to MR Imaging: Diagnostic Steps in Adenomyosis. <i>BioMed Research International</i> , 2017, 2017, 1-6.	1.9	20
14	Quantitative chemical proteomics reveals a Plk1 inhibitor-compromised cell death pathway in human cells. <i>Cell Research</i> , 2014, 24, 1141-1145.	12.0	19
15	The Small-Molecule Inhibitor MRIA9 Reveals Novel Insights into the Cell Cycle Roles of SIK2 in Ovarian Cancer Cells. <i>Cancers</i> , 2021, 13, 3658.	3.7	17
16	Laparoscopy or laparotomy as the way of entrance in myoma enucleation. <i>Archives of Gynecology and Obstetrics</i> , 2017, 296, 709-720.	1.7	16
17	The Prognostic Relevance of the Proliferation Markers Ki-67 and Plk1 in Early-Stage Ovarian Cancer Patients With Serous, Low-Grade Carcinoma Based on mRNA and Protein Expression. <i>Frontiers in Oncology</i> , 2020, 10, 558932.	2.8	15
18	Modelling the Functions of Polo-Like Kinases in Mice and Their Applications as Cancer Targets with a Special Focus on Ovarian Cancer. <i>Cells</i> , 2021, 10, 1176.	4.1	11

#	ARTICLE	IF	CITATIONS
19	A dimerization-dependent mechanism regulates enzymatic activation and nuclear entry of PLK1. <i>Oncogene</i> , 2022, 41, 372-386.	5.9	10
20	Control of dataset bias in combined Affymetrix cohorts of triple negative breast cancer. <i>Genomics Data</i> , 2014, 2, 354-356.	1.3	9
21	The Future of Adhesion Prophylaxis Trials in Abdominal Surgery: An Expert Global Consensus. <i>Journal of Clinical Medicine</i> , 2022, 11, 1476.	2.4	9
22	The Role of DAPK1 in the Cell Cycle Regulation of Cervical Cancer Cells and in Response to Topotecan. <i>Journal of Cancer</i> , 2022, 13, 728-743.	2.5	7
23	TFF3 Expression as Stratification Marker in Borderline Epithelial Tumors of the Ovary. <i>Pathology and Oncology Research</i> , 2018, 24, 277-282.	1.9	5
24	Association of Polo-Like Kinase 3 and PhosphoT273 Caspase 8 Levels With Disease-Related Outcomes Among Cervical Squamous Cell Carcinoma Patients Treated With Chemoradiation and Brachytherapy. <i>Frontiers in Oncology</i> , 2019, 9, 742.	2.8	5
25	Histotype-specific analysis of acid ceramidase expression in ovarian cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 855-862.	2.8	5
26	Impact of re-excision of residual adjacent vulvar intraepithelial neoplasia (VIN III) and histological tumour-free margin (hTFM) on survival in primary squamous cell carcinoma of vulva. <i>Archives of Gynecology and Obstetrics</i> , 2018, 298, 945-950.	1.7	4
27	Adenomyosis and Myomata: Risks, Problems, and Complications in Diagnosis and Therapy of Adenomyosis and Myomata. <i>BioMed Research International</i> , 2018, 2018, 1-2.	1.9	4
28	IMP3 Expression in Borderline Tumors of the Ovary. <i>Anticancer Research</i> , 2017, 37, 583-588.	1.1	4